Filing Flows

Filing Flows › DexCom (DXCM) › Recalls, complaints & regulation

DexCom (DXCM): recalls and clinical trials

DexCom (DXCM) beyond its filings: 4 recalls in the last 12 months (18 in five years, 10 Class I); 5 active clinical trials.

Latest recalls

DexCom's latest quarter

DexCom, Q3 2026: revenue $1.3B (+11% year over year), operating margin 24.3%, net earnings $275M, operating cash flow $326M. The chart follows the revenue to costs, profit and cash.

Questions

Has DexCom had any recalls?

18 recalls on file over five years from the FDA, CPSC and NHTSA; 4 in the last 12 months.

How many clinical trials does DexCom have?

5 active studies on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.